KYMR
Kymera Therapeutics, Inc.
There isn't enough reported data to score KYMR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
KYMR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
KYMR's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KYMR PE Valuation
KYMR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
KYMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect KYMR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KYMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.63 | -$0.03 |
| Q2 2026 | -$3.25 | +$0.23 |
| Q1 2026 | -$3.58 | -$0.47 |
| Q4 2025 | -$3.69 | -$0.71 |
| Q3 2025 | -$3.60 | -$1.26 |
| Q2 2025 | -$3.48 | -$1.06 |
| Q1 2025 | -$3.11 | -$0.60 |
| Q4 2024 | -$2.98 | -$0.46 |
KYMR lost $3.63 per share over the past year, about the same as its loss the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over KYMR on earnings quality, reporting a profit while its opponent remains loss making.
KYMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $65M | +466% |
| Q1 2026 | $34.4M | +55% |
| Q4 2025 | $2.9M | -61% |
| Q3 2025 | $2.8M | -26% |
| Q2 2025 | $11.5M | -55% |
| Q1 2025 | $22.1M | +115% |
| Q4 2024 | $7.4M | -85% |
| Q3 2024 | $3.7M | -21% |
KYMR's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -116% | +621 points |
| Q1 2026 | -245% | +92 points |
| Q4 2025 | -3411% | -2319 points |
| Q3 2025 | -3347% | -1419 points |
| Q2 2025 | -737% | -538 points |
| Q1 2025 | -337% | +225 points |
| Q4 2024 | -1092% | -1052 points |
| Q3 2024 | -1928% | -712 points |
KYMR's operating margin was −116% last quarter, up 621 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over KYMR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over KYMR on profitability, with a higher operating margin.
KYMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.2M | -$50.9M |
| Q2 2026 | -$54.5M | +$6M |
| Q1 2026 | -$89.3M | -$9.7M |
| Q4 2025 | -$66.9M | -$4.1M |
| Q3 2025 | -$27.3M | +$22.7M |
| Q2 2025 | -$60.6M | -$13M |
| Q1 2025 | -$79.6M | -$32.6M |
| Q4 2024 | -$62.7M | -$59.1M |
KYMR has burned cash in almost every quarter: −$289M over the past year, against −$230M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over KYMR on cash generation, producing positive trailing cash flow while its opponent burns cash.
KYMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +1.9M shares |
| 1 year | +15% | +12.8M shares |
| 3 years | +71% | +41.7M shares |
| 5 years | +97% | +49.4M shares |
| Available history | +125% | +55.6M shares |
KYMR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KYMR Net Leverage
KYMR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
KYMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.8 | Neutral |
| Stochastic | 80.4 | Overbought |
KYMR's weekly RSI is 63 (neutral) and its Stochastic is 80 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KYMR PE vs Healthcare Sector
KYMR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KYMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.6 | 9.1% above |
| 20 week MA | $115.4 | 10% above |
| 50 week MA | $95.2 | 34% above |
| 100 week MA | $69.0 | 84% above |
| 200 week MA | $50.6 | 151% above |
KYMR is in an uptrend: it's above all five of its weekly moving averages, and 151% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
KYMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.3 | $86.1 | +159% |
| 2021 | $86.1 | $61.8 | -28% |
| 2022 | $61.8 | $26.5 | -57% |
| 2023 | $26.5 | $25.5 | -3.9% |
| 2024 | $25.5 | $40.1 | +58% |
| 2025 | $40.1 | $81.3 | +103% |
| 2026 YTD | $81.3 | $127.2 | +56% |
KYMR's yearly returns have swung widely, from +159% in 2020 to −57% in 2022. It's up 56% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KYMR on returns for 2026, with the stronger performance.